MAPT and Alzheimer disease: In the present study, we demonstrate that this novel aβComAb, GW-23B7, infused intraperitoneally (i.p.)could access the brains of triple-transgenic (3 × Tg) AD mice with both Aβ and tau pathologies and induce a significant cognitive rescue by reducing pathological oligomeric conformers of both tau and Aβ.